Zobrazeno 1 - 10
of 1 932
pro vyhledávání: ''
Autor:
Daniel Moj, Nicola Ammer, Babette Aicher, Jan-Georg Wojtyniak, Thorsten Lehr, Michael Teifel, Herbert Sindermann, Hannah Britz, Nina Hanke
Zoptarelin doxorubicin is a fusion molecule of the chemotherapeutic doxorubicin and a luteinizing hormone-releasing hormone receptor (LHRHR) agonist, designed for drug targeting to LHRHR positive tumors. The aim of this study was to establish a physi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c5e9a18956370d7aca5ee1061fd910
Autor:
Cintia V Cruz, Paula Schaiquevich, Carlos A Pérez Montilla, Gabriela Reyes Valenzuela, Paulo Cáceres Guido, Facundo García Bournissen, Roberto Caraballo
Background: Cannabidiol (CBD) is a nonpsychoactive natural product that has been increasingly used as a promising new drug for the management of neurological conditions such as refractory epilepsy. Development of rapid and sensitive methods to quanti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6450fcd9997e851e4532077b12d00108
https://doi.org/10.1097/ftd.0000000000000846
https://doi.org/10.1097/ftd.0000000000000846
Autor:
Caroline Flora Samer, Camille Lenoir, Amine Niederer, Jules Alexandre Desmeules, Victoria Rollason, Youssef Daali
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 30-43 (2022)
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 1, Pp 30-43 (2022)
Xenobiotics can interact with cytochromes P450 (CYPs), resulting in drug–drug interactions, but CYPs can also contribute to drug–disease interactions, especially in the case of inflammation, which downregulates CYP activities through pretranscrip
Publikováno v:
Clinical Pharmacology in Drug Development. 11:220-234
LYT-100 (deupirfenidone) is a selectively deuterated form of pirfenidone under development for the treatment of inflammatory and fibrotic diseases, including interstitial lung disease. Adverse events associated with antifibrotics can be a barrier to
Publikováno v:
British Journal of Clinical Pharmacology. 88:1885-1896
Aim: Metamizole (dipyrone) is a prodrug not detectable in serum or urine after oral ingestion. The primary metabolite is 4-methylaminoantipyrine (4-MAA), which can be N-demethylated to 4-aminoantipyrine (4-AA) or oxidized to 4-formylaminoantipyrine (
Publikováno v:
ACS Pharmacol Transl Sci
[Image: see text] Microdialysis coupled to an analytical system can be used to continuously monitor unbound protein analytes in any biological fluid, tissue, or organ of animals. To date, no application of microdialysis has been performed to simultan
Autor:
Senthil Packiasabapathy, Michael A. Heathman, Senthilkumar Sadhasivam, Blessed W Aruldhas, Sara K. Quinney, Andrea R. Masters, Hongyu Gao, Brian R. Overholser, Reynold C. Ly
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1183-1194 (2021)
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 10, Pp 1183-1194 (2021)
Methadone is a synthetic opioid used as an analgesic and for the treatment of opioid abuse disorder. The analgesic dose in the pediatric population is not well‐defined. The pharmacokinetics (PKs) of methadone is highly variable due to the variabili
Autor:
Rocco C. Venuto, Kathleen M. Tornatore, Joseph D. Consiglio, Calvin J. Meaney, Louise M. Cooper, Daniel A. Brazeau, Gregory E. Wilding
Publikováno v:
J Clin Pharmacol
Mycophenolic acid exhibits significant interpatient pharmacokinetic variability attributed to factors including race, sex, concurrent medications, and enterohepatic circulation of the mycophenolic acid glucuronide metabolite to mycophenolic acid. Thi
Autor:
Silvia Scabini, Antonio D'Avolio, Rosario Urbino, Jessica Cusato, Francesca Canta, Luca Brazzi, Simone Mornese Pinna, Giorgia Montrucchio, Chiara Bonetto, Silvia Corcione, Giovanni Di Perri, Valeria Avataneo, Amedeo De Nicolò, Francesco Giuseppe De Rosa
Publikováno v:
British Journal of Clinical Pharmacology
Remdesivir is one of the most encouraging treatments against SARS‐CoV‐2 infection. After intravenous infusion, RDV is rapidly metabolized (T1/2 1h) within the cells to its active adenosine triphosphate analogue form (GS‐443902) and, then, it ca
Publikováno v:
Clinical Pharmacology in Drug Development
GLPG1205 is a novel agent being investigated for the treatment of idiopathic pulmonary fibrosis. GLPG1205 may be concomitantly administered with pirfenidone in future clinical development; therefore, the potential for GLPG1205 to interact with enzyme